Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Columbia University

Memorial Sloan Kettering Cancer Center

Medshine Discovery Inc.

China Resources Pharmaceutical Holdings Company Limited

Minghui Pharmaceutical Limited

Yuanshan Yao

Shuhui Chen

Jian Li

Yuan Chen

Bin Chen

Chengshuai Yang

Ran Xu

Hongwei Li

Ronald C Breslow

Paul A Marks

Lingyun Wu

Ao Qiong Li

Zhaoguo Chen

Zhensheng Huang

Adaickapillai Mahendran

Fang Liu

Feng Gao

Guoqing Cao

Lele Zhao

Dongdong Tian

Zhaoyin Wang

Bing Yao

Sheng Zhang

Ao Li

Li Zhang

The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.

Cyclic molecules as Bruton's tyrosine kinase inhibitor

Provided are a tricyclic compound as shown in formula (I) as a CRTH2 inhibitor, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a solvate thereof, and the use thereof in treating diseases related to CRTH2 receptors. 

Tricyclic compound as CRTH2 inhibitor

Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof. 

Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity

Disclosed are a crystal form of an indole derivative (compound 1) and a pharmaceutical composition and preparation method thereof. The crystal form is used to prepare a drug for treating a disease related to a CRTH2 receptor. 

Crystal form of indole derivative and preparation method and use thereof

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor. 

Indole derivative used as CRTH2 inhibitor

The present invention provides a compound having the structure: 

Selective HDAC6 inhibitors

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof. 

Isoquinolinesulfonyl derivative as RHO kinase inhibitor

Growing community of inventors

Shanghai, China

Yuanshan Yao